Liver transplantation in the mouse: Insights into liver immunobiology, tissue injury, and allograft tolerance

Shinichiro Yokota, Osamu Yoshida, Yoshihiro Ono, David A. Geller, Angus W. Thomson – 28 December 2015 – The surgically demanding mouse orthotopic liver transplant model was first described in 1991. It has proved to be a powerful research tool for the investigation of liver biology, tissue injury, the regulation of alloimmunity and tolerance induction, and the pathogenesis of specific liver diseases.

Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans‐splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization

Joseph Ralph Kallini, Ahmed Gabr, Laura Kulik, Daniel Ganger, Robert Lewandowski, Bartley Thornburg, Riad Salem – 28 December 2015

Noncirrhotic complete obliterative portal vein thrombosis: Novel management using trans‐splenic transjugular intrahepatic portosystemic shunt with portal vein recanalization

Joseph Ralph Kallini, Ahmed Gabr, Laura Kulik, Daniel Ganger, Robert Lewandowski, Bartley Thornburg, Riad Salem – 28 December 2015

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Sammy Saab, Sarah H. Park, Masashi Mizokami, Masao Omata, Alessandra Mangia, Ed Eggleton, Yanni Zhu, Steven J. Knox, Phil Pang, Mani Subramanian, Kris Kowdley, Nezam H. Afdhal – 24 December 2015 – Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus ≥65 years among subjects enrolled in phase 3 trials.

Subscribe to